CytoDyn (CYDY) Interest Expenses (2010 - 2026)
CytoDyn's (CYDY) quarterly Interest Expenses came in at $1.8 million in Q1 2026, up 56.96% YoY from $1.1 million in Q1 2025, and down 52.68% on a QoQ basis from $3.8 million in Q4 2025.
CytoDyn (CYDY) Interest Expenses (2010 - 2026) Analysis & Trends
CytoDyn (CYDY) has 17 years of Interest Expenses data on file, last reported at $1.8 million in Q1 2026.
- Quarterly Interest Expenses rose 56.96% year-over-year to $1.8 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was $1.8 million (down 97.0% YoY) and the FY2025 annual result came in at $126.2 million, up 110.68% from the prior year.
- Interest Expenses declined to $1.8 million in Q1 2026, from $3.8 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $56.4 million in Q2 2024 to a low of -$24.4 million in Q2 2023.
- A 5-year average of $7.4 million and a median of $3.0 million in 2025 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2023 — Interest Expenses plunged 555.23% — and 2024, when it surged 331.35%.
- Tracing CYDY's Interest Expenses over 5 years: stood at $3.3 million in 2022, then plunged by 65.07% to $1.2 million in 2023, then retreated by 0.26% to $1.2 million in 2024, then soared by 226.53% to $3.8 million in 2025, then sank by 52.68% to $1.8 million in 2026.
- The last three Interest Expenses figures came in at $1.8 million (Q1 2026), $3.8 million (Q4 2025), and $3.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | CytoDyn | 258.01 Mn | 258.01 Mn | - | 1.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | 1.79 Mn |
| Feb 28, 2026 | 1.79 Mn |
| Nov 30, 2025 | 3.79 Mn |
| Nov 30, 2025 | 3.79 Mn |
| Aug 31, 2025 | 3.04 Mn |
| Aug 31, 2025 | 3.04 Mn |
| May 31, 2025 | 26.83 Mn |
| May 31, 2025 | 26.83 Mn |
| Feb 28, 2025 | 1.14 Mn |
| Feb 28, 2025 | 1.14 Mn |
| Nov 30, 2024 | 1.16 Mn |
| Nov 30, 2024 | 1.16 Mn |
| Aug 31, 2024 | 1.17 Mn |
| Aug 31, 2024 | 1.17 Mn |
| May 31, 2024 | 56.39 Mn |
| May 31, 2024 | 56.39 Mn |
| Feb 29, 2024 | 1.15 Mn |
| Feb 29, 2024 | 1.15 Mn |
| Nov 30, 2023 | 1.16 Mn |
| Nov 30, 2023 | 1.16 Mn |